229 related articles for article (PubMed ID: 35850360)
1. Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas.
Gkountakos A; Mafficini A; Lou E; Malleo G; Salvia R; Calicchia M; Silvestris N; Racila E; Amin K; Veronese N; Brunetti O; Antonini P; Ingravallo G; Mattiolo P; Saponaro C; Nappo F; Simbolo M; Bariani E; Lonardi S; Fassan M; Milella M; Lawlor RT; Scarpa A; Luchini C
Hum Pathol; 2022 Oct; 128():124-133. PubMed ID: 35850360
[TBL] [Abstract][Full Text] [Related]
2. The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
Yang Y; Ding Y; Gong Y; Zhao S; Li M; Li X; Song G; Zhai B; Liu J; Shao Y; Zhu L; Pang J; Ma Y; Ou Q; Wu X; Zhang Z
BMC Cancer; 2022 Feb; 22(1):186. PubMed ID: 35180847
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells.
Simbolo M; Silvestris N; Malleo G; Mafficini A; Maggino L; Cocomazzi A; Veghini L; Mombello A; Pezzini F; Sereni E; Martelli FM; Gkountakos A; Ciaparrone C; Piredda ML; Ingravallo G; Paolino G; Nappo F; Rapposelli IG; Frassinetti L; Saragoni L; Lonardi S; Pea A; Paiella S; Fassan M; Brunetti O; Cingarlini S; Salvia R; Milella M; Corbo V; Lawlor RT; Scarpa A; Luchini C
Mod Pathol; 2023 Sep; 36(9):100251. PubMed ID: 37355152
[TBL] [Abstract][Full Text] [Related]
4. Undifferentiated Sarcomatoid Carcinoma of the Pancreas: From Histology and Molecular Pathology to Precision Oncology.
Gkountakos A; Simbolo M; Bariani E; Scarpa A; Luchini C
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163206
[TBL] [Abstract][Full Text] [Related]
5. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
6. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
[TBL] [Abstract][Full Text] [Related]
7. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
9. Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets.
Faber EB; Krause HB; Amin K; Walker P; Hosein PJ; Shields AF; Lenz HJ; Prakash A; Goel S; Oberley M; Malleo G; Luchini C; Hwang J; Florou V; Garrido-Laguna I; Lou E
JCO Precis Oncol; 2024 May; 8():e2300595. PubMed ID: 38723231
[TBL] [Abstract][Full Text] [Related]
10. Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma.
Gómez-Tomás Á; Pumarega J; Alguacil J; Amaral AFS; Malats N; Pallarès N; Gasull M; Porta M;
Environ Mol Mutagen; 2019 Oct; 60(8):693-703. PubMed ID: 31066938
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer.
Zhang X; Mao T; Zhang B; Xu H; Cui J; Jiao F; Chen D; Wang Y; Hu J; Xia Q; Ge W; Li S; Yue M; Ma J; Yao J; Wang Y; Wang Y; Shentu D; Zhang X; Chen S; Bai Y; Wang Y; Zhang X; Liu Q; Sun Y; Fu D; Liu Y; Xiong L; Wang L
EBioMedicine; 2022 Mar; 77():103897. PubMed ID: 35231699
[TBL] [Abstract][Full Text] [Related]
12. Undifferentiated Carcinoma with Osteoclast-like Giant Cells of the Pancreas: Molecular Genetic Analysis of 13 Cases.
Hrudka J; Kalinová M; Ciprová V; Moravcová J; Dvořák R; Matěj R
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542259
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
[TBL] [Abstract][Full Text] [Related]
14. Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.
Choi MH; Mejlænder-Andersen E; Manueldas S; El Jellas K; Steine SJ; Tjensvoll K; Sætran HA; Knappskog S; Hoem D; Nordgård O; Hovland R; Molven A
BMC Cancer; 2019 Jan; 19(1):11. PubMed ID: 30611220
[TBL] [Abstract][Full Text] [Related]
15. KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas.
Krasinskas AM; Moser AJ; Saka B; Adsay NV; Chiosea SI
Mod Pathol; 2013 Oct; 26(10):1346-54. PubMed ID: 23599154
[TBL] [Abstract][Full Text] [Related]
16. Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas.
Lenkiewicz E; Malasi S; Hogenson TL; Flores LF; Barham W; Phillips WJ; Roesler AS; Chambers KR; Rajbhandari N; Hayashi A; Antal CE; Downes M; Grandgenett PM; Hollingsworth MA; Cridebring D; Xiong Y; Lee JH; Ye Z; Yan H; Hernandez MC; Leiting JL; Evans RM; Ordog T; Truty MJ; Borad MJ; Reya T; Von Hoff DD; Fernandez-Zapico ME; Barrett MT
Cancer Res; 2020 Oct; 80(20):4324-4334. PubMed ID: 32928922
[TBL] [Abstract][Full Text] [Related]
17. TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma.
Zhou Y; Jin J; Ji Y; Zhang J; Fu N; Chen M; Wang J; Qin K; Jiang Y; Cheng D; Deng X; Shen B
J Transl Med; 2023 Dec; 21(1):872. PubMed ID: 38037073
[TBL] [Abstract][Full Text] [Related]
18. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
[TBL] [Abstract][Full Text] [Related]
19. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
